The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine.
- Author:
Yu FENG
1
;
Yue-Yong XIAO
;
Shao-Dan LI
;
Ming-Xiong LIN
;
Yin ZHANG
;
Hai-Ming WANG
;
Min LI
;
Xiao ZHANG
;
Ke CAO
;
Yu-Fei YE
;
Li ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; adverse effects; therapeutic use; Biomarkers, Tumor; metabolism; Brachytherapy; adverse effects; Carcinoma, Non-Small-Cell Lung; drug therapy; radiotherapy; Combined Modality Therapy; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; drug therapy; radiotherapy; Male; Middle Aged; Quality of Life; Treatment Outcome
- From: Chinese journal of integrative medicine 2012;18(9):663-669
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo investigate the effects of brachytherapy with computed tomography-guided percutaneous radioactive I-125 seeds interstitial implantation (ISI) synchronized chemotherapy and Chinese medicine (CM) for the treatment of advanced stage of non-small cell lung cancer (NSCLC).
METHODSNinety patients diagnosed with NSCLC by biopsy were randomly assigned to three groups: the synchronized therapy group (A), the chemotherapy plus CM-treated group (B), and the chemotherapy-treated group (C); a 2-month course of treatment was administered to them all. The effectiveness of treatment was evaluated based on tumor size, tumor markers (carcinoembryonic, squamous cell carcinoma-associated antigen, and cytokeratin 19 fragment), clinical symptoms, and quality of life (QOL) in patients.
RESULTSThe total effective rates of Groups A to C were 83.33%, 46.67%, and 43.33%, respectively. The tumor markers were reduced obviously in Group A, showing signifificant difference compared with those in the other two groups. Additionally, QOL was elevated and cancer-related symptoms were alleviated more signifificant in Group A than those in Group C (all P<0.05).
CONCLUSIONThe synchronized therapy of I-125 implantation with chemotherapy and CM was a safe therapeutic method and can be regarded as a new mode for treatment of advanced-stage NSCLC.
